Edition:
United Kingdom

PhaseRx Inc (PZRX.OQ)

PZRX.OQ on NASDAQ Stock Exchange Capital Market

0.41USD
4:48pm GMT
Change (% chg)

$-0.02 (-4.75%)
Prev Close
$0.43
Open
$0.40
Day's High
$0.44
Day's Low
$0.38
Volume
137,740
Avg. Vol
165,205
52-wk High
$1.95
52-wk Low
$0.38

Chart for

About

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $10.53
Shares Outstanding(Mil.): 11.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares

* PHASERX RECEIVES DECISION FROM THE NASDAQ HEARINGS PANEL FOR CONTINUED LISTING OF SHARES

13 Dec 2017

BRIEF-PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA

* PHASERX RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR PRX-ASL FROM EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-PhaseRx reports Q3 loss per share $0.23

* PhaseRx reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Phaserx gets delisting notice from NASDAQ

* Says receipt of delisting notice from NASDAQ informing trading in co's stock will be suspended from NASDAQ at opening of business on Nov 1​ Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Phaserx announces corporate restructuring and review of strategic alternatives

* PhaseRx announces corporate restructuring and review of strategic alternatives

13 Oct 2017

BRIEF-PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL

* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-Phaserx reports Q2 loss per share $0.30

* Phaserx reports second quarter 2017 financial results and provides corporate update

10 Aug 2017

BRIEF-PhaseRx files for stock and warrants offering of up to $15 mln

* PhaseRx Inc files for stock and warrants offering of up to $15 million - sec filing Source text: (http://bit.ly/2sBPItI) Further company coverage:

21 Jun 2017

Earnings vs. Estimates